gastrointestinal disease DiaSorin to Acquire Luminex for $1.8B DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years. DARPA Programs Leveraging Host-Response Testing, CRISPR for Future Pandemic Preparedness Premium DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing. Appendiceal Cancer Sequences Suggest Distinct Mutation Patterns in Early-, Late-Onset Cases With clinical sequencing data for almost 400 appendiceal cancer cases, researchers identified somatic differences in individuals diagnosed with the disease before the age of 50. Twist Bioscience, Takeda Pharma Partner to Develop Antibodies for Oncology, Rare Diseases Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodie Australian Firm Genetic Signatures to Enter US Market With Syndromic Kit for GI Conditions Premium To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization. Jan 8, 2020 Applied BioCode Receives FDA Clearance for Syndromic Respiratory Pathogen Panel Oct 9, 2019 Japanese Informatics Firm Genomedia Sees SCRUM Cancer Project as Path to Wider Adoption Premium Oct 9, 2019 Mobidiag Gets CE Mark for Intestinal Parasites Test Oct 8, 2019 Serosep, Quidel Ink US Distribution Deal for GI Panel Sep 4, 2019 uBiome Declares Bankruptcy, Offers Assets for Sale Jun 12, 2019 FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System Apr 11, 2019 Hirschsprung's Disease Genetic Analysis Reveals Mix of Common, Rare Risk Variants Nov 30, 2018 Gallstone Disease Meta-Analysis Leads to Bile Transport, Cholesterol Pathways Oct 11, 2018 Undiagnosed Diseases Network Reports Diagnostic Rates, Impact on Treatment Oct 2, 2018 Ariel Precision Medicine Launches Clinical Decision Support for NGS Pancreatitis Assay Premium Sep 4, 2018 Diverticular Disease GWAS Leads to Dozens of New Risk Loci Aug 2, 2018 Becton Dickinson Reports 41 Percent Increase in Fiscal Q3 Revenues Feb 5, 2018 Qiagen to Enter Multiplex Infectious Disease Testing Market With Stat-Dx Buy Premium Jan 4, 2018 Applied BioCode Submits MDx Platform, GI Panel for 510(k) Clearance Nov 27, 2017 Interlux to Distribute Mobidiag Products in Estonia Nov 7, 2017 Progenity Closes $125M Series B Financing Round Jun 29, 2017 Rare Gut Condition Linked to Single Gene Mutations, Hyperactivation of Complement System Apr 20, 2017 Applied Biocode to Submit Gastrointestinal Pathogen Panel to FDA in Bid to Displace Luminex Premium Jan 23, 2017 Mobidiag Gets CE IVD Mark for Sample Prep System Jan 17, 2017 Mobidiag Inks South Africa Distribution Agreement Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.